Gene therapies help lung cancer victims — but not if they aren’t tested
Large clinicial trials proved that early-term lung cancer patients with specific genetic markers can live significantly longer, post-surgery, if they receive medical therapies based on their genetic signatures. Research by a local team based at Baptist Cancer Center and the University of Memphis School of Public Health shows that 40%, or two of out every five patients locally, did not get the testing. (The Daily Memphian file)
In the Mid-South, 40% of patients aren’t tested because doctors and hospitals aren’t on board, according to research in a national journal.
Topics
Dr. Raymond Osarogiagbon Matthew Smeltzer lung cancer Dr. Neil HayesJane Roberts
Longtime journalist Jane Roberts is a Minnesotan by birth and a Memphian by choice. She's lived and reported in the city more than two decades. She covers business news and features for The Daily Memphian.
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.